Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study.
Biomark Med
; 6(2): 231-3, 2012 Apr.
Article
in En
| MEDLINE
| ID: mdl-22448798
ABSTRACT
AIM:
Early markers of response to chemotherapy, measured by blood markers and imaging, may ultimately lead to tailored therapies that avoid cumulative toxicity. MATERIALS &METHODS:
We performed a small pilot study to compare early changes in levels of circulatory tumor cells (CTCs) with changes in tumor proliferation, using metabolic imaging with [(18)F] 3´-deoxy-3´-fluorothymidine PET (FLT-PET) in women with advanced breast cancer, before and during docetaxel therapy.RESULTS:
In those individuals in whom we could detect CTCs, a decrease in CTC count correlated with a decrease in FLT-PET signal, within 2 weeks.CONCLUSION:
Combined, these two technologies are likely to provide a powerful, albeit expensive, tool to assess immediate responses to therapy.
Full text:
1
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Bridged-Ring Compounds
/
Drug Monitoring
/
Taxoids
/
Positron-Emission Tomography
/
Neoplastic Cells, Circulating
Type of study:
Evaluation_studies
Limits:
Female
/
Humans
Language:
En
Year:
2012
Type:
Article